$SRRK News

Scholar Rock Receives FDA's Priority Review Voucher For Isembyld

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)

Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy

Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72

Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75

Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65

Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70

Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58

HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript